Peptide library
Liraglutide: evidence profile
Approved product · Randomized evidence
Read each statement within its named product, route and evidence scope. The reading exercise below helps you examine a claim; it does not choose care.
Evidence record
- Product and route
- Subcutaneous injection.
- Approval scope
- Saxenda: weight management for eligible patients.
- Mechanism
- Activates the GLP-1 receptor.
- Evidence
- Randomized trials.
- Limits
- Check other products separately.
- Safety context
- The label warns about severe gastrointestinal reactions.
A reading exercise
For a liraglutide report, set up a worksheet with separate lists for the people described at the beginning and the records contributing to the final result. Copy the stated inclusion rules above each list. Follow an imaginary participant through the worksheet, allowing for a later measurement to be unavailable or a record to fall outside a stated analysis rule. Keep those possibilities distinct from leaving the broader study. Then examine which group a sentence about the result actually names. Your worksheet should explain the connection between that sentence and its contributing records, without treating the initial list as an automatic description of every later calculation.
Questions to take away
- Whose records contribute to the final result described in this sentence?
- Could a missing measurement affect the calculation without establishing that someone left the study?
- Which inclusion rule connects the starting list to the final analysis?
Sources
The dates below identify each source check. Publication of this page does not mean every source was checked again.